Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03QWO
|
||||
| Former ID |
DCL000771
|
||||
| Drug Name |
Dexefaroxan
|
||||
| Synonyms |
Dexefaroxan [INN]; (+)-(r)-2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-2-imidazoline; 2-[(2R)-2-ethyl-3H-1-benzofuran-2-yl]-4,5-dihydro-1H-imidazole
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Parkinson's disease [ICD9: 332; ICD10:G20] | Phase 2 | [1] | ||
| Schizophrenia [ICD9: 295; ICD10:F20] | Discontinued in Phase 2 | [2] | |||
| Company |
Pierre Fabre
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C13H16N2O
|
||||
| Canonical SMILES |
CCC1(CC2=CC=CC=C2O1)C3=NCCN3
|
||||
| InChI |
1S/C13H16N2O/c1-2-13(12-14-7-8-15-12)9-10-5-3-4-6-11(10)16-13/h3-6H,2,7-9H2,1H3,(H,14,15)/t13-/m1/s1
|
||||
| InChIKey |
RATZLMXRALDSJW-CYBMUJFWSA-N
|
||||
| CAS Number |
CAS 143249-88-1
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Adenosine A2a receptor | Target Info | Agonist | [2] | |
| Nicotinic acetylcholine receptor | Target Info | Agonist | [2] | ||
| KEGG Pathway | Rap1 signaling pathway | ||||
| Calcium signaling pathway | |||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Vascular smooth muscle contraction | |||||
| Parkinson's disease | |||||
| Alcoholism | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| PathWhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | ||||
| Reactome | NGF-independant TRKA activation | ||||
| Adenosine P1 receptors | |||||
| G alpha (s) signalling events | |||||
| Surfactant metabolism | |||||
| WikiPathways | Nucleotide GPCRs | ||||
| Monoamine Transport | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| NGF signalling via TRKA from the plasma membrane | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | Effects of the alpha 2-adrenoreceptor antagonist dexefaroxan on neurogenesis in the olfactory bulb of the adult rat in vivo: selective protection against neuronal death. Neuroscience. 2003;117(2):281-91. | ||||
| REF 2 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.